Poor adherence to adjuvant endocrine therapy remains an issue among patients with breast cancer. What can oncologists and patients do to improve long-term use?
The US Federal Trade Commission has warned brand-name drugmakers they could face legal action if they improperly list patents with federal health regulators.
Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst.